The North America metastatic cancer drugs market is expected to reach US$ 27,989.14 million by 2028 from US$ 21,414.73 million in 2021; it is estimated to grow at a CAGR of 3.9% from 2021 to 2028.

A few most common cancer types include lung cancer, breast cancer, colon cancer, rectum cancer, and prostate cancer. The condition develops in ~400,000 children every year. Carcinogenic infections, including Helicobacter pylori, hepatitis B virus, human papillomavirus (HPV), hepatitis C virus, and Epstein-Barr virus, caused ~13% of cancer cases in 2018 regionally. The International Agency for Research on Cancer (IARC) projects that the number of new cancer cases and cancer-related deaths worldwide would grow ~1.6–1.7 fold to reach 29.5 million by 2040 from 16.4 million in 2018. Further, according to the American Society of Clinical Oncology, in 2021, ~290,560 people (287,850 women and 2,710 men) in the US were diagnosed with invasive breast cancer. Breast cancer in females has now surpassed lung cancer as the most commonly diagnosed cancer worldwide. ~2,261,419 women were diagnosed with breast cancer in 2020.
All the observations recorded about cancer in the US over the past several decades show that metastatic cancer accounts for up to 90% of all cancer deaths each year. These numbers have motivated doctors and researchers to find new ways to treat metastasis, which occurs when cancer spreads beyond its point of origin. In the US, 6% of women were diagnosed with metastatic breast cancer in the first diagnosis. Such rise in the prevalence of cancer and metastatic cancer is driving the growth of the metastatic cancer drug market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the metastatic cancer drugs market growth in the coming years. The market is expected to grow at a good CAGR during the forecast period.
North America Metastatic Cancer Drugs Market Revenue and Forecast to 2028 (US$ Million)

North America Metastatic Cancer Drugs Market Segmentation

The North America metastatic cancer drugs market is segmented on the basis of cancer type, route of administration, drug class, product, and end user. Based on cancer type, the market is segmented into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Based on route of administration, the market is bifurcated into intravenous and intramuscular. Based on drug class , the North America metastatic cancer drugs market is segmented into HER2 inhibitors, immune checkpoint inhibitors, parp inhibitors, kinase inhibitors, and others. Based on product, the market is segmented into branded, generics, and biosimilars . Based on end user, the market is segmented into hospital, specialty clinic, and others. By country, the North America metastatic cancer drugs market is segmented into the US, Mexico, and Canada.

North America Metastatic Cancer Drugs Market – Companies Mentioned

AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; F. HOFFMANN-LA ROCHE LTD.; Novartis AG; Astrazeneca; Eli Lilly and Company; MERCK KGaA ; Pfizer Inc. (Arena Pharmaceutical GmbH); and Johnson and Johnson Services, Inc. are among the leading companies in the North America metastatic cancer drugs market.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Metastatic Cancer Drugs Market – By Cancer Type
1.3.2 North America Metastatic Cancer Drugs Market – By Route of Administration
1.3.3 North America Metastatic Cancer Drugs Market – By Drug Class
1.3.4 North America Metastatic Cancer Drugs Market – By Product
1.3.5 North America Metastatic Cancer Drugs Market – By End User
1.3.6 North America Metastatic Cancer Drugs Market – By Country
2. North America Metastatic Cancer Drugs Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Metastatic Cancer Drugs Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America– PEST Analysis
4.3 Expert Opinion
5. North America Metastatic Cancer Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 High Prevalence of Metastatic Cancer
5.1.2 Government Initiatives to Support Developments in Cancer Treatment
5.2 Market Restraints
5.2.1 High Cost of Oncology Drugs
5.3 Market Opportunities
5.3.1 Investments in Artificial Intelligence for Oncology Drug Development
5.4 Future Trends
5.4.1 Increase in Launch of Metastatic Cancer Drugs
5.5 Impact analysis
6. North America Metastatic Cancer Drugs Market – Country Analysis
6.1 North America Metastatic Cancer Drugs Market Revenue Forecast and Analysis
7. North America Metastatic Cancer Drug Market Analysis – By Cancer Type
7.1 Overview
7.2 North America Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)
7.2.1 North America: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)
7.3 Breast Cancer
7.3.1 Overview
7.3.2 Breast Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Lung Cancer
7.4.1 Overview
7.4.2 Lung Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Liver Cancer
7.5.1 Overview
7.5.2 Liver Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Hematological Cancer
7.6.1 Overview
7.6.2 Hematological Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Brain Cancer
7.7.1 Overview
7.7.2 Brain Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.8 Prostate Cancer
7.8.1 Overview
7.8.2 Prostate Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.9 Pancreatic Cancer
7.9.1 Overview
7.9.2 Pancreatic Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
8. North America Metastatic Cancer Drug Market – By Route of Administration
8.1 Overview
8.2 North America Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)
8.2.1 North America: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
8.3 Intravenous
8.3.1 Overview
8.3.2 Intravenous: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Intramuscular
8.4.1 Overview
8.4.2 Intramuscular: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Oral
8.5.1 Overview
8.5.2 Oral: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9. North America Metastatic Cancer Drug Market – By Drug Class
9.1 Overview
9.2 North America Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)
9.2.1 North America: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)
9.3 HER2 Inhibitors
9.3.1 Overview
9.3.2 HER2 Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Immune Checkpoints Inhibitors
9.4.1 Overview
9.4.2 Immune Checkpoints Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9.5 PARP Inhibitors
9.5.1 Overview
9.5.2 PARP Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Kinase Inhibitors
9.6.1 Overview
9.6.2 Kinase Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
10. North America Metastatic Cancer Drug Market – By Product
10.1 Overview
10.2 North America Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)
10.2.1 North America: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)
10.3 Branded
10.3.1 Overview
10.3.2 Branded: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Generics and Biosimilars
10.4.1 Overview
10.4.2 Generics and Biosimilars: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
11. North America Metastatic Cancer Drug Market – By End User
11.1 Overview
11.2 North America Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)
11.2.1 North America: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)
11.3 Hospital
11.3.1 Overview
11.3.2 Hospitals: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
11.4 Specialty Clinic
11.4.1 Overview
11.4.2 Specialty Clinics: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
11.5 Others
11.5.1 Overview
11.5.2 Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
12. North America Metastatic Cancer Drugs Market – Regional Analysis
12.1 North America Metastatic Cancer Drugs Market Revenue Forecast and Analysis
12.1.1 North America Metastatic Cancer Drugs Market Revenue Forecast and Analysis
12.1.1.1 US: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.1.1.1 US: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.1.1.2 US: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)
12.1.1.1.3 US: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
12.1.1.1.4 US: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)
12.1.1.1.5 US: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)
12.1.1.1.6 US: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)
12.1.1.2 Canada: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.1.2.1 Canada: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.1.2.2 Canada: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)
12.1.1.2.3 Canada: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
12.1.1.2.4 Canada: North America Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)
12.1.1.2.5 Canada: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)
12.1.1.2.6 Canada: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)
12.1.1.3 Mexico: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.1.3.1 Mexico: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.1.3.2 Mexico: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)
12.1.1.3.3 Mexico: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
12.1.1.3.4 Mexico: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)
12.1.1.3.5 Mexico: North America Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)
12.1.1.3.6 Mexico: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)
13. North America Metastatic Cancer Drug Market –Industry Landscape
13.1 Overview
13.2 Growth Strategies in the North America Metastatic Cancer Drug Market, 2021-2028
13.3 Inorganic Developments
13.3.1 Overview
13.4 Organic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 AbbVie Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Amgen Inc.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Bristol-Myers Squibb Company
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 F. HOFFMANN-LA ROCHE LTD.
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Novartis AG
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Astrazeneca
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Eli Lilly and Company.
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 MERCK KGaA
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Pfizer Inc. (Arena Pharmaceutical GmbH)
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Johnson and Johnson Services, Inc.
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms

LIST OF TABLES

Table 1. North America: North America Metastatic Cancer Drug Market, – Revenue and Forecast to 2028 (USD Million)
Table 2. North America: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)
Table 3. North America: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 4. North America: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)
Table 5. North America: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)
Table 6. North America: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 7. US: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)
Table 8. US: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 9. US: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)
Table 10.   US: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)
Table 11.   US: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 12.   Canada: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)
Table 13.   Canada: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 14.   Canada: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)
Table 15.   Canada: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)
Table 16.   Canada: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 17.   Mexico: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)
Table 18.   Mexico: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 19.   Mexico: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)
Table 20.   Mexico: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)
Table 21.   Mexico: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 22.   Recent Inorganic Growth Strategies in the North America Metastatic Cancer Drug Market
Table 23.   Recent Organic Growth Strategies in the North America Metastatic Cancer Drug Market
Table 24.   Glossary of Terms, North America Metastatic Cancer Drugs Market
 

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America Metastatic Cancer Drugs Market.
● Highlights key business priorities in order to assist companies to realign their business strategies.
● The key findings and recommendations highlight crucial progressive industry trends in North America Metastatic Cancer Drugs Market, thereby allowing players across the value chain to develop effective long-term strategies.
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
● Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
● Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

The List of Companies – North America Metastatic Cancer Drugs Market

● AbbVie Inc.                                                                                                        
● Amgen Inc.                                                                                                         
● Bristol-Myers Squibb Company                                                                 
● F. HOFFMANN-LA ROCHE LTD.                                                                   
● Novartis AG                                                                                                       
● Astrazeneca                                                                                                      
● Eli Lilly and Company                                                                                     
● MERCK KGaA                                                                                                    
● Pfizer Inc. (Arena Pharmaceutical GmbH)                                             
● Johnson and Johnson Services, Inc.